CN1181968A - Hypoglycemic medicine composition - Google Patents
Hypoglycemic medicine composition Download PDFInfo
- Publication number
- CN1181968A CN1181968A CN97120257A CN97120257A CN1181968A CN 1181968 A CN1181968 A CN 1181968A CN 97120257 A CN97120257 A CN 97120257A CN 97120257 A CN97120257 A CN 97120257A CN 1181968 A CN1181968 A CN 1181968A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- salviae miltiorrhizae
- rhizoma polygonati
- herba cistanches
- bombyx bombycis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine composition for curing diabetes has active component, which is extraction prepared with six Chinese medicinal materials of silworm cocoon, Astragalus membranaceus, saline cistanche, solomonseal, red sage and Poria and through water decoction and alcohol precipitation.
Description
The present invention relates to a kind of new Chinese medicine pharmaceutical composition, particularly a kind of pharmaceutical composition for the treatment of diabetes.
The category that the treatment diabetes spp " is quenched one's thirst " in the traditional Chinese medical science, the traditional Chinese medical science will be quenched one's thirst branch and will be three, on disappear at lung, in disappear at stomach, diabetes due to kidney-deficiency is at kidney, three types of diabetes is divided and rule and can be cured the disease, and the present invention cures on the basis of the different theories of diabetes under study for action, and proposing the treatment primary disease should be from spleen, kidney, liver the three start with, send out in middle-aged and elderly people well in conjunction with primary disease, and diet, feelings will, be overworked for a very long period, senilism often influences each other, therefore think spleen suffer from a deficiency of the kidney decline be disease this, congestion blocks, functional activity of QI being not smooth is the mark of disease, when with tonify deficiency, dispel and become silted up with using the treatment primary disease, the present invention is according to above-mentioned principle, and the elite Six-element Chinese prescription of getting has been made Chinese medicine composition of the present invention.
Chinese medicine composition of the present invention, its active component is the extract of Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria Six-element Chinese medicine, this extract is to make by the method for decocting in water precipitate with ethanol, Chinese medicine composition of the present invention, be mixed and made into by extract and medicine acceptable carrier above-mentioned Six-element Chinese medicine, this pharmaceutical composition can comprise various pharmaceutical dosage forms, and these pharmaceutical dosage forms can be tablet, capsule, oral liquid, electuary, patch, pill, powder, injection etc.Chinese medicine composition of the present invention shows the effect of tangible blood sugar lowering in zoopery, below be relevant animal experimental data: one, experiment below the influence of blood glucose is used to illustrate the influence of the present composition to alloxan model mice blood glucose.Value after group dosage fasting glucose value model blood glucose value was taken medicine one month
G/kg mmol/L mmol/L mmol/L normal group water 20ml 6.65 6.18 model group 7.14 28.11 26.04 positive control 0.0125 5.89 26.35 9.89 (phenformin) low dose group 8.25 8.45 25.77 21.62 high dose group 16.5 6.21 25.96 16.77 conclusions: gavage the present composition after one month for the alloxan model mice, high low dose group all can obviously reduce the blood glucose value of animal pattern. Two, to the influence of amount of drinking water and voided volume:following experiment is used to illustrate that the present composition influences group dosage number of animals amount of drinking water voided volume to alloxan model mice amount of drinking water, urine amount
G/kg ml ml normal group water 20ml 10 2.3 1.5 model group 10 5.1 3.9 positive control 0.0125 10 2.7 1.8 (insoral) low dose group 8.25 10 4.8 3.6 high dose group 16.5 10 4.0 3.1 conclusions: gavage the present composition after one month for the alloxan model mice, high dose group can obviously reduce amount of drinking water and the voided volume of animal pattern.
Specific embodiments of the invention are as follows: prescription: Bombyx bombycis 50g, Radix Astragali 107g, Herba Cistanches 107g,
Rhizoma Polygonati 107g, Radix Salviae Miltiorrhizae 72g, Poria 107g method for making: above Six-element, Bombyx bombycis add 50 times in water, soak 2 minutes, decoct 3 minutes, filter and are concentrated into relative density 1.15; All the other five tastes decoct with water 2 times, add 10 times of water gagings at every turn, decoct respectively 2 hours, 1.5 hours, filter, merging filtrate, it is 1.15 that filtrate is concentrated into relative density, above concentrated solution merges, and adds ethanol to containing alcohol amount 60%, places, precipitation filters, and filtrate recycling ethanol is to 800ml, add water to 1000ml again, cold preservation 72 hours filters, embedding, sterilization, promptly.
Claims (8)
1, be the pharmaceutical composition of active component with Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria extract.
2, the pharmaceutical composition of claim 1, wherein the amount of Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria extract is physiologically acceptable amount.
3, the pharmaceutical composition of claim 1, wherein the amount of each component is Bombyx bombycis 40-60g, Radix Astragali 90-120g, Herba Cistanches 90-120g, Rhizoma Polygonati 90-120g, Radix Salviae Miltiorrhizae 60-80g, Poria 90-120g in Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, the Poria extract.
4, the manufacture method of the pharmaceutical composition of claim 1 is characterized in that, Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria extract and medicine acceptable carrier are mixed.
5, the manufacture method of the pharmaceutical composition of claim 1, wherein the manufacturing of Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria extract is made by the decocting in water alcohol precipitating method.
6, the manufacture method of the pharmaceutical composition of claim 5, wherein the manufacture method of Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria extract is after Bombyx bombycis is soaked decoction separately, merge with the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria water cooking liquid, add ethanol precipitation after concentrating, obtain behind the recovery ethanol.
7, the pharmaceutical composition of claim 1 is tablet, capsule, oral liquid, electuary, patch, pill, powder, injection.
8, the pharmaceutical composition of claim 1 is an oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97120257A CN1094358C (en) | 1997-11-07 | 1997-11-07 | Hypoglycemic medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97120257A CN1094358C (en) | 1997-11-07 | 1997-11-07 | Hypoglycemic medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1181968A true CN1181968A (en) | 1998-05-20 |
| CN1094358C CN1094358C (en) | 2002-11-20 |
Family
ID=5175845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97120257A Expired - Fee Related CN1094358C (en) | 1997-11-07 | 1997-11-07 | Hypoglycemic medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1094358C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341523C (en) * | 1999-05-25 | 2007-10-10 | 株式会社使用技术 | Volatile liquid composition for inhibiting hyperglycemia, and its volatiling device and its use |
| CN114404568A (en) * | 2022-01-16 | 2022-04-29 | 重庆理工大学 | Sericin polypeptide injection and application thereof |
-
1997
- 1997-11-07 CN CN97120257A patent/CN1094358C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341523C (en) * | 1999-05-25 | 2007-10-10 | 株式会社使用技术 | Volatile liquid composition for inhibiting hyperglycemia, and its volatiling device and its use |
| CN114404568A (en) * | 2022-01-16 | 2022-04-29 | 重庆理工大学 | Sericin polypeptide injection and application thereof |
| CN114404568B (en) * | 2022-01-16 | 2023-12-26 | 重庆理工大学 | Sericin polypeptide injection preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1094358C (en) | 2002-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100420472C (en) | Diabetes treating medicine | |
| CN102755594B (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN101095736B (en) | Chinese traditional medicine composition for treating acute and chronic pharyngitis, tonsillitis and method of making the same | |
| CN102274447A (en) | Medicinal composition for treating diabetes | |
| CN101524471A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN102258710A (en) | Traditional Chinese medicine composition for treating type II diabetes | |
| CN103977361A (en) | Traditional Chinese medicine for treating ascites caused by cirrhosis and preparation method thereof | |
| CN1087625C (en) | Traditional Chinese medicine preparation for treating colitis | |
| CN103623292A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103446503A (en) | Traditional Chinese medicine composition for treating type II diabetes mellitus | |
| CN100434093C (en) | 'Kidney-Benefiting' glucose injection and its preparing process | |
| CN101406598B (en) | Chinese medicine composite for treating diabetes and preparation method thereof | |
| CN100404066C (en) | Chinese medicine for treating diabetes mellitus and its preparation | |
| CN102178733A (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN101607031B (en) | Medicated wine for curing and preventing diabetes mellitus, preparation method and application method thereof | |
| CN1094358C (en) | Hypoglycemic medicine composition | |
| CN103301355A (en) | Preparation method of chronic renal failure colon dialysate | |
| CN102988856A (en) | Medicine for treating infantile salivation | |
| CN1443544A (en) | Chinese medicine Jiangtang Tongmailing for curing diabetes and preventing and curing complicating diseases and its preparation method | |
| CN104013806A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN1792372A (en) | Traditional Chinese medicine prepn. for treating diabetes | |
| CN104248742A (en) | Traditional Chinese medicinal composition for treating cancers, and preparation method thereof | |
| CN111759999B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for preventing and/or treating diabetes | |
| CN105943841A (en) | Traditional Chinese medicine composition for treating type II diabetes | |
| CN100475238C (en) | Medication for HIV and manufacturing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIREN PHARMA LINZHOU CO., LTD. Free format text: FORMER OWNER: SHENGDING CANBAO CO., LTD. LINZHOU Effective date: 20101111 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 456550 NO.50, LONGSHAN ROAD, CHENGGUAN TOWN, LINZHOU CITY, HE NAN PROVINCE TO: 456550 INDUSTRIAL PARK, YUANKANG TOWN, LINZHOU CITY, ANYANG CITY, HE NAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101111 Address after: 456550, Henan City, Anyang province Linzhou city original town industrial zone Patentee after: Ji Ren pharmaceutical Linzhou Co., Ltd. Address before: 456550 No. 50 Longshan Road, Chengguan Town, Henan, Linzhou Patentee before: Shengding Canbao Co., Ltd. Linzhou |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20021120 Termination date: 20131107 |